menu
    • menu
    [{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Upsher-Smith Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Upsher-Smith Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"JW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"JW Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Seoul National University Bundang Hospital","sponsor":"JW Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Seoul National University Bundang Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Bundang Hospital \/ JW Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Seoul National University Bundang Hospital \/ JW Pharmaceutical"},{"orgOrder":0,"company":"Korea University Anam Hospital","sponsor":"Daewon Pharm. Co., Ltd | Samjin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Korea University Anam Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea University Anam Hospital \/ Daewon Pharm. Co., Ltd | Samjin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Korea University Anam Hospital \/ Daewon Pharm. Co., Ltd | Samjin Pharmaceutical"},{"orgOrder":0,"company":"JW Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitavastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"JW Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"JW Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"JW Pharmaceutical \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Livazo

    Menu

    Livazo

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Basilea Pharmaceutica

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Biomedical Advanced Research and Development Authority

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 05, 2025

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Biomedical Advanced Research and Development Authority

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Korea University Anam Hospital

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Korea University Anam Hospital

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Daewon Pharm. Co., Ltd | Samjin Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes M...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 10, 2025

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Daewon Pharm. Co., Ltd | Samjin Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Seoul National University Bundang Hospital

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Seoul National University Bundang Hospital

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : JW Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Pitavastatin on Bone

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 11, 2024

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : JW Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Upsher-Smith Laboratories

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Upsher-Smith Launches Pitavastatin Tablets

                            Details : Pitavastatin tablet is a HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in Adult patients with primary hyperlipidemia or mixed dyslipidemia.

                            Product Name : Livalo-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 11, 2023

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            JW Pharmaceutical

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            JW Pharmaceutical

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            JW Pharmaceutical

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            JW Pharmaceutical

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2020

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Fudan University

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed

                            Fudan University

                            Country arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Peking University People's Hospital | Wanbang Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 01, 2018

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Peking University People's Hospital | Wanbang Biopharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Seoul National University Hospital

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed

                            Seoul National University Hospital

                            South Korea arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : JW Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 20, 2016

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : JW Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 03, 2015

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            National Institute of Allergy and Infectious Diseases

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            National Institute of Allergy and Infectious Diseases

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : National Heart, Lung, and Blood Institute | Kowa Pharmaceuticals America | Gilead Sciences | Massachusetts General Hospital | NEAT ID Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 22, 2015

                            Lead Product(s) : Pitavastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : National Heart, Lung, and Blood Institute | Kowa Pharmaceuticals America | Gilead Sciences | Massachusetts General Hospital | NEAT ID Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth